SHIRE HUMAN GENETIC THERAPIES INC DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Related Companies

Shire's new HGT team, the former TKT, specializes in discovering, developing and commercializing protein therapeutics primarily for the treatment of genetic diseases. This business extends Shire's reach by strengthening its portfolio and pipeline with a range of new therapeutic possibilities for patients suffering with genetic diseases. 'By adding the proprietary protein technologies of TKT to the proven commercialization kno...

Shire's new HGT team, the former TKT, specializes in discovering, developing and commercializing protein therapeutics primarily for the treatment of genetic diseases. This business extends Shire's reach by strengthening its portfolio and pipeline with a range of new therapeutic possibilities for patients suffering with genetic diseases. 'By adding the proprietary protein technologies of TKT to the proven commercialization knowhow of Shire, we've generated an entity worth far more than the sum of its parts,' says David Pendergast, Shire HGT's Executive Vice President and General Manager. 'Together, we've signalled our intention to continue growing as market leaders in serving specialist physicians and their patients.' TKT, acquired in 2005, is an excellent strategic fit for Shire, adds Dr Pendergast, former executive vice president and chief operating officer of TKT who has 33 years of pharmaceutical industry experience. 'Both Shire and TKT leverage relationships with highly specialized physicians and focus on the development of products that offer a strong benefit-to-risk ratio. Both also care enormously for the patients and families that are ultimately served by our product lines.' Shire HGT provides specific disease area expertise, a high-quality product portfolio and a low-risk, well-balanced development pipeline with one marketed product and two attractive late-stage products directed at genetic diseases. In addition, protein replacement therapy provides a good platform for further expansion through research and product in-licensing. Shire HGT's approach to product development is to use protein therapies to replace lost biological function resulting from a malfunctioning or missing gene in affected patients. It does not conduct high-risk discovery research and protein replacement therapies generally benefit from fast development timelines. These drugs have a high success rate in reaching the market and normally benefit from long lifecycles once marketed due to orphan drug status exclusivity (seven years in the US and ten years in the EU) and robust patent protection.

Company profile for SHIRE HUMAN GENETIC THERAPIES INC

SHIRE HUMAN GENETIC THERAPIES INC

SHIRE HUMAN GENETIC THERAPIES INC

About

Contact Details

EVENTS

Webinars & Exhibitions

PRESENTATION(s)

VIDEO(s)

DIGITAL CONTENT

2 News

DEVELOPMENTS

DOSSIERs // Finished Dosage Formulations

2 Dossiers

2 FDA Orange Book

INSPECTIONS & REGISTRATIONS

14 FDA

What are you looking for?